Latigo Biotherapeutics
LTGOLatigo Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing innovative, non-opioid pain medicines that target the Nav1.8 voltage-gated sodium channel.
Latigo Biotherapeutics has filed an S-1 registration statement with the SEC and is not yet trading. Financial statements will appear here once it begins reporting as a public company.
S-1 Filings
Registration statements filed with the SEC ahead of the planned listing
Competitors
By market cap
By revenue growth
Profile
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing innovative, non-opioid pain medicines that target the Nav1.8 voltage-gated sodium channel. The company aims to provide rapid and effective pain relief without the risk of addiction or the central nervous system side effects associated with opioids. Their platform leverages deep expertise in pain biology and translational clinical models to address both acute and chronic musculoskeletal pain.
Latigo is a clinical-stage innovator in the emerging Nav1.8 inhibitor class, positioning itself as a potential provider of the first systemic analgesic with an opioid-free label claim.
Questions, answered.
- Who are Latigo Biotherapeutics's competitors?
- Latigo Biotherapeutics's key competitors include Vertex Pharmaceuticals Incorporated, Eli Lilly and Company, Merck Sharp & Dohme LLC, and others. These companies compete in similar markets and product categories.
- Who does Latigo Biotherapeutics partner with?
- Latigo Biotherapeutics's notable partners include Lieber Institute for Brain Development, Lotus Clinical Research, LLC.
- Where is Latigo Biotherapeutics headquartered?
- Latigo Biotherapeutics is headquartered in United States of America.